| 12/31/2009 | CV | Celldex assumes obligations of CuraGen's 4% convertibles after merger
|
| 10/2/2009 | CV | CuraGen amends indenture of 4% convertibles following Celldex merger
|
| 7/31/2009 | CV | CuraGen buys back $1.64 million 4% convertibles subordinated notes
|
| 5/14/2008 | CV | CuraGen buys back $50.9 million of 4% convertibles
|
| 11/15/2007 | CV | CuraGen buys back $22.2 million 4% convertibles
|
| 5/19/2006 | CV | Market Commentary: SafeNet improves dollar-neutral on federal probe; American Axle likely to be converted, analyst says
|
| 12/13/2005 | CV | Market Commentary: Omnicare edges higher; Intel, Ceradyne on deck; price talk emerges on Entergy mandatories
|
| 9/20/2005 | BTCV | CuraGen buys back $23.9 million 6% convertibles
|
| 9/8/2005 | CV | Market Commentary: Convertibles trade mixed, with Amgen, Nabors edging up, Cypress Semiconductor down
|
| 9/6/2005 | CV | Market Commentary: Chiron trades mixed, but Curagen gains; Dobson Communications to price $150 million issue
|
| 8/10/2005 | CV | CuraGen to repurchase convertibles using stock offering proceeds
|
| 7/25/2005 | BTCV | CuraGen buys back $39.9 million 6% convertibles due 2007 for $37.7 million
|
| 7/8/2005 | CV | Market Commentary: Biotechs, chips lead convertibles mostly higher; Charming Shoppes, Henry Schein trade higher
|
| 5/12/2005 | CV | Market Commentary: GM, Ford head renewed move south; Delta convertibles idle after 7.7s swapped for equity
|
| 4/26/2005 | CV | Market Commentary: Curagen plunges amid big sellout; Level 3 founders; XM rises, Sirius dips; Wynn bid up; airlines plunge
|
| 3/15/2005 | CV | Market Commentary: Central Parking up; Whole Foods off as Wild Oats rises; Ivax better, Curagen slides; Leucadia easier
|
| 10/19/2004 | CV | Market Commentary: Delta convertibles dive 1 point each; Jakks Pacific slammed by lawsuit; Ford, GM off
|
| 10/13/2004 | CV | Market Commentary: Delta convertibles rise sharply; Amkor buyers heartened; Lucent edges up, Apex easier
|
| 4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
| 3/16/2004 | CV | CuraGen greenshoe partially exercised, raising convertibles to $110 million
|
| 2/12/2004 | CVDD | S&P rates CuraGen converts CCC
|
| 2/11/2004 | CV | New Issue: CuraGen upsized $100 million convertible yields 4.0%, up 37%
|
| 2/11/2004 | CV | Market Commentary: Disney steals show; Echostar cast as takeover target, too; Safeguard advanced
|
| 2/10/2004 | CV | Market Commentary: New deals active; Solectron loses 0.5 point; AMR reoffered at 98.5; CuraGen, InterMune ahead
|
| 2/9/2004 | CV | Market Commentary: Calpine 4s add 1.25 points on tender; Juniper whacked 11.25 points; four deals tossed to market
|
| 2/9/2004 | CV | CuraGen $75 million convertible talked at 3.75-4.25% yield, up 33-37%
|
| 11/10/2003 | CV | Market Commentary: Biotech paper grabs attention as yield-hungry investors invade market
|
